A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-06. Anything still debated is marked as such rather than presented as settled.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The French naturalist Georges-Louis Leclerc (1707–1788) underlined the benefits of donkey milk in his Histoire Naturelle. Some effects have been supported by systematic and scientific studies starting from the mid-1800s, especially by Russian doctors. Donkey and mare's milk are very similar, and it is assumed they have similar properties. The beneficial effects of equid milk, from the first historical sources to the present day, are aimed at:
=== Foreign nationals === The people on death row include foreign nationals, many of whom were convicted of drug-related offences. These inmates come from a diverse range of countries, including Australia, Bangladesh, China, Ghana, India, Indonesia, Malaysia, the Netherlands, Nigeria, Pakistan, the Philippines, Portugal, Sri Lanka, Thailand, the United Kingdom, and Vietnam. Figures released by the Singapore government show that between 1993 and 2003, 36% of those executed were foreigners, including some residents in Singapore (half of Singapore residents are foreigners).
Light therapy, also called phototherapy or bright light therapy, is the exposure to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, neonatal jaundice, and skin wound infections. Treating skin conditions such as neurodermatitis, psoriasis, acne vulgaris, and eczema with ultraviolet light is called ultraviolet light therapy.
Sources: en.wikipedia.org
== Matrix-assisted laser desorption/ionization == For matrix-assisted laser desorption/ionization (MALDI) mass spectrometry a solid or liquid sample is mixed with a matrix solution, to help the sample avoid processes such as aggregation or precipitation, while helping the sample remain stable during the ionization process. The matrix crystallizes with the sample and is then deposited on a sample plate, which can be made of a range of materials, from inert metals to inert polymers. The matrix containing the sample molecules is then transferred to the gas phase by pulsed laser irradiation. The makeup of the matrix, interactions between the sample and the matrix, and how the sample is deposited are all extremely important during sample preparation to ensure the best possible results. The selection of a matrix is the first step when preparing samples for MALDI analysis. The primary goals of the matrix are to absorb the energy from a laser, thus transferring it to the analyte molecules, and to separate the analyte molecules from each other. A consideration that should be taken into account when choosing a matrix is what type of analyte ion is expected or desired. Knowing the acidity or basicity of the analyte molecule compared with the acidity or basicity of the matrix, for example, is valuable knowledge when choosing a matrix. The matrix should not compete with the analyte molecule, so the matrix should not want to form the same type of ion as the analyte.
=== First radiation protection regulations === A leaflet published by the German Radiological Society (DRG) in 1913 was the first systematic approach to radiation protection. The physicist and co-founder of the society, Bernhard Walter (1861-1950), was one of the pioneers of radiation protection. The International Commission on Radiological Protection (ICRP) and the International Commission on Radiation Units and Measurements (ICRU) were established at the Second International Congress of Radiology in Stockholm in 1928. In the same year, the first international radiation protection recommendations were adopted and each country represented was asked to develop a coordinated radiation control program. The United States representative, Lauriston Taylor of the US Bureau of Standards (NSB), formed the Advisory Committee on X-Ray and Radium Protection, later renamed the National Committee on Radiation Protection and Measurements (NCRP). The NCRP received a Congressional charter in 1964 and continues to develop guidelines to protect individuals and the public from excessive radiation. In the years that followed, numerous other organizations were established by almost every president.
=== Melting points === The melting points of the alkanes follow a similar trend to boiling points for the same reason as outlined above. That is, (all other things being equal) the larger the molecule the higher the melting point. However, alkanes' melting points follow a more complex pattern, due to variations in the properties of their solid crystals. One difference in crystal structure that even-numbered alkanes (from hexane onwards) tend to form denser-packed crystals compared to their odd-numbered neighbors. This causes them to have a greater enthalpy of fusion (amount of energy required to melt them), raising their melting point. A second difference in crystal structure is that even-numbered alkanes (from octane onwards) tend to form more rotationally ordered crystals compared to their odd-numbered neighbors. This causes them to have a greater entropy of fusion (increase in disorder from the solid to the liquid state), lowering their melting point. While these effects operate in opposing directions, the first effect tends to be slightly stronger, leading even-numbered alkanes to have slightly higher melting points than the average of their odd-numbered neighbors. This trend does not apply to methane, which has an unusually high melting point, higher than both ethane and propane. This is because it has a very low entropy of fusion, attributable to its high molecular symmetry and the rotational disorder in solid methane near its melting point (Methane I).
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.